International Journal of Cardiology
Volume 139, Issue 2 , Pages 123-133 , 4 March 2010

Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial

  • Kenneth W. Mahaffey

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, United States
    • Corresponding Author InformationCorresponding author. Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, United States. Tel.: +1 919 668 8845; fax: +1 919 688 7059.
    • ,
  • Simon T. Tonev

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, United States
    • ,
  • Sarah A. Spinler

      Affiliations

    • University of the Sciences, Philadelphia, PA, United States
    • ,
  • Glenn N. Levine

      Affiliations

    • Baylor College of Medicine, Houston, TX, United States
    • ,
  • Richard Gallo

      Affiliations

    • Montreal Heart Institute, Montreal, Quebec, Canada
    • ,
  • John Ducas

      Affiliations

    • Health Sciences Centre and St. Boniface Hospital, Winnipeg, Manitoba, Canada
    • ,
  • Shaun G. Goodman

      Affiliations

    • Canadian Heart Research Centre, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Elliott M. Antman

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, United States
    • ,
  • Richard C. Becker

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, United States
    • ,
  • Anatoly Langer

      Affiliations

    • Canadian Heart Research Centre, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Harvey D. White

      Affiliations

    • Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    • ,
  • Philip E. Aylward

      Affiliations

    • Department of Cardiology, Flinders Medical Centre, Bedford Park, Australia
    • ,
  • Jacques J. Col

      Affiliations

    • Clinique Universitaire St. Luc, Brussels, Belgium
    • ,
  • James J. Ferguson

      Affiliations

    • The Medicines Company, Parsippany, NJ, United States
    • ,
  • Robert M. Califf

      Affiliations

    • Duke Clinical Research Institute, Durham, NC, United States
    • ,
  • on behalf of the SYNERGY Trial Investigators

Received 24 October 2007 ,Revised 22 September 2008 ,Accepted 12 October 2008.

References 

  1. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999–2002. JAMA. 2004;291:2847–2850
  2. Yancy WS, Olsen MK, Curtis LH, Schulman KA, Cuffe MS, Oddone EZ. Variations in coronary procedure utilization depending on body mass index. Arch Intern Med. 2005;165:1381–1387
  3. Mensah GA, Mokdad AH, Ford E, et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin. 2004;22:485–504
  4. National Heart, Lung, and Blood Institute in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda, MD: National Institutes of Health, National Heart, Lung, and Blood Institute, 1998.
  5. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation. 2002;106:1893–1900
  6. Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2002;23:1809–1840
  7. Cohen M, Mahaffey KW, Berdan L. Superiority of enoxaparin low-molecular-weight heparin over unfractionated heparin in patients with no prior antithrombin therapy or maintained on consistent antithrombin therapy: results from SYNERGY. J Am Coll Cardiol. 2006;48:1346–1354
  8. SYNERGY Executive Committee . The SYNERGY trial: study design and rationale. Am Heart J. 2002;143:952–960
  9. Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA. 2004;292:45–54
  10. SYNERGY Executive Committee. Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors. The SYNERGY trial: study design and rationale. Am Heart J. 2002;143:952–960
  11. Rao SV, Mahaffey KW, Antman EM, et al. Predictors of major bleeding and transfusion in SYNERGY: effects of pretreatment variables and treatment assignment. J Am Coll Cardiol. 2005;45(Suppl A):247A;Abstract 850-5
  12. Mahaffey KW, Yang Q, Pieper KS, et al. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. J Gen Intern Med. 2008;23:310–316
  13. Stone CJ, Koo CY. Additive splines in statistics. Proc Stat Comp Sect Am Statist Assoc. 1985;45–48
  14. Mahaffey KW, Califf RM, Cohen M, et al. Consistent therapy with enoxaparin is superior to unfractionated heparin in SYNERGY. J Am Coll Cardiol. 2005;45(Suppl A):231A;Abstract 1118–218
  15. Diercks DB, Roe MT, Mulgund J, et al. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. Am Heart J. 2006;152:140–148
  16. Gruberg L, Mercado N, Milo S, et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: the obesity paradox II?. Am J Cardiol. 2005;95:439–444
  17. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox?. J Am Coll Cardiol. 2002;39:578–584
  18. Mora S, Yanek LR, Moy TF, Fallin MD, Becker LC, Becker DM. Interaction of body mass index and Framingham risk score in predicting incident coronary disease in families. Circulation. 2005;111:1871–1876
  19. Cassidy AE, Bielak LF, Zhou Y, et al. Progression of subclinical coronary atherosclerosis: does obesity make a difference?. Circulation. 2005;111:1877–1882
  20. Kurki TS, Kataja M. Preoperative prediction of postoperative morbidity in coronary artery bypass grafting. Ann Thorac Surg. 1996;61:1740–1745
  21. Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short- and long-term outcomes in patients undergoing coronary revascularization. Insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol. 2002;39:834–840
  22. Sprecher DL, Pearce GL. How deadly is the “deadly quartet”? A post-CABG evaluation.. J Am Coll Cardiol. 2000;36:1159–1165
  23. Schwann TA, Habib RH, Zacharias A, et al. Effects of body size on operative, intermediate, and long-term outcomes after coronary artery bypass operation. Ann Thorac Surg. 2001;71:521–530discussion 530–531
  24. Spinler SA, Inverso SM, Cohen M, et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33–41
  25. White HD, Kleiman NS, Mahaffey KW, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042–1050
  26. Bazinet A, Almanric K, Brunet C. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res. 2005;116:41–50
  27. Sanderink GJ, Le Liboux A, Jariwala N. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin Pharmacol Ther. 2002;72:308–318
  28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145–153
  29. Berger PB, Best PJ, Topol EJ, et al. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. Am Heart J. 2005;149:869–875
  30. Macie C, Forbes L, Foster GA, Douketis JD. Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome. Chest. 2004;125:1616–1621
  31. Coats AJ. Ethical authorship and publishing. Int J Cardiol. 2009;131:149–150

PII: S0167-5273(08)01066-8

doi: 10.1016/j.ijcard.2008.10.008

International Journal of Cardiology
Volume 139, Issue 2 , Pages 123-133 , 4 March 2010

Article Tools

* Image Usage & Resolution